Literature DB >> 30506232

Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.

Maneerat Raksayot1, Natthaya Chuaypen1, Apichaya Khlaiphuengsin1, Nutcha Pinjaroen2, Sombat Treeprasertsuk3, Yong Poovorawan4, Yasuhito Tanaka5, Pisit Tangkijvanich6.   

Abstract

BACKGROUND: This study was aimed at evaluating the association between single nucleotide polymorphisms (SNPs) in the PNPLA3, NCAN, TM6SF2 and MBOAT7 and hepatocellular carcinoma (HCC) development in Thai patients according to underlying etiologies of liver disease.
METHODS: These SNPs were determined by allelic discrimination in blood samples of 105 healthy controls and 530 patients with HCC [270 with hepatitis B virus (HBV-HCC), 131 with hepatitis C virus (HCV-HCC), and 129 with non-B, non-C HCC (NBNC-HCC) matched for age and gender].
RESULTS: G allele of PNPLA3 rs738409 variant was significantly higher in NBNC-HCC (49%) compared to healthy controls (32%), HBV-HCC (32%) and HCV-HCC (31%) (P < 0.001). T allele of TM6SF2 rs58542926 was more prevalent in NBNC-HCC (24%) than in healthy controls (8%), HBV-HCC (10%) and HCV-HCC (12%) (P < 0.001). The distribution of NCAN (rs2228603) and MBOAT7 (rs641738) was not different between groups. In multivariate logistic regression analysis, PNPLA3 rs738409 (OR 2.06, 95% CI 1.24-3.43; P = 0.005) and TM6SF2 rs58542926 (OR 2.22, 95% CI 1.34-3.65; P = 0.002) were independently associated with NBNC-HCC compared to viral-related HCC (VR-HCC). The proportion of patients with NBNC-HCC increased significantly along with the increase of the number of risk alleles. There was no association between these SNPs and overall survival in patients with HCC.
CONCLUSIONS: These data showed that PNPLA3 and TM6SF2 polymorphisms were independently linked to NBNC-HCC but not HBV- or HCV-HCC in Thai populations. In addition, the risk genotypes might interact with each other through tumor development in patients with NBNC-HCC.

Entities:  

Keywords:  Hepatocellular carcinoma; PNPLA3; Polymorphisms; TM6SF2; Viral hepatitis

Mesh:

Substances:

Year:  2018        PMID: 30506232     DOI: 10.1007/s00535-018-01533-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  40 in total

Review 1.  From fat to inflammation.

Authors:  Christopher Paul Day
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

Review 2.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  Association of hepatitis viruses with hepatocellular carcinoma in Thailand.

Authors:  P Tangkijvanich; P Hirsch; A Theamboonlers; I Nuchprayoon; Y Poovorawan
Journal:  J Gastroenterol       Date:  1999-04       Impact factor: 7.527

Review 4.  Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis.

Authors:  Pierre Nahon; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2012-05-16       Impact factor: 25.083

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 6.  Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

7.  Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities.

Authors:  Christopher M Jenkins; David J Mancuso; Wei Yan; Harold F Sims; Beverly Gibson; Richard W Gross
Journal:  J Biol Chem       Date:  2004-09-10       Impact factor: 5.157

8.  Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.

Authors:  Elizabeth K Speliotes; Laura M Yerges-Armstrong; Jun Wu; Ruben Hernaez; Lauren J Kim; Cameron D Palmer; Vilmundur Gudnason; Gudny Eiriksdottir; Melissa E Garcia; Lenore J Launer; Michael A Nalls; Jeanne M Clark; Braxton D Mitchell; Alan R Shuldiner; Johannah L Butler; Marta Tomas; Udo Hoffmann; Shih-Jen Hwang; Joseph M Massaro; Christopher J O'Donnell; Dushyant V Sahani; Veikko Salomaa; Eric E Schadt; Stephen M Schwartz; David S Siscovick; Benjamin F Voight; J Jeffrey Carr; Mary F Feitosa; Tamara B Harris; Caroline S Fox; Albert V Smith; W H Linda Kao; Joel N Hirschhorn; Ingrid B Borecki
Journal:  PLoS Genet       Date:  2011-03-10       Impact factor: 5.917

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more
  10 in total

Review 1.  Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.

Authors:  Becky Ching-Yeung Yu; Deborah Kwok; Vincent Wai-Sun Wong
Journal:  J Clin Exp Hepatol       Date:  2019-02-07

2.  Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.

Authors:  Natthaya Chuaypen; Surachate Siripongsakun; Pantajaree Hiranrat; Natthaporn Tanpowpong; Anchalee Avihingsanon; Pisit Tangkijvanich
Journal:  PLoS One       Date:  2022-06-13       Impact factor: 3.752

3.  The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta-analysis of 24,147 subjects.

Authors:  Xinpei Chen; Pengcheng Zhou; Luo De; Bo Li; Song Su
Journal:  Mol Genet Genomic Med       Date:  2019-07-15       Impact factor: 2.183

Review 4.  PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.

Authors:  Xiaocheng Charlie Dong
Journal:  Front Med (Lausanne)       Date:  2019-12-17

Review 5.  Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes.

Authors:  Tingting Shi; Hideki Kobara; Kyoko Oura; Tsutomu Masaki
Journal:  J Hepatocell Carcinoma       Date:  2021-02-11

6.  Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B.

Authors:  Rei-Chi Hsueh; Wan-Jung Wu; Chih-Lin Lin; Chun-Jen Liu; Yi-Wen Huang; Jui-Ting Hu; Chih-Feng Wu; Feng-Yu Sung; Wen-Jie Liu; Ming-Whei Yu
Journal:  J Hepatocell Carcinoma       Date:  2022-04-11

7.  PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.

Authors:  Bisma Rauff; Ali Amar; Badr Alzahrani; Shafiq A Chudhary; Bilal Nasir; Saqib Mahmood; Munir Ahmad Bhinder; Muhammad Faheem
Journal:  BMC Gastroenterol       Date:  2022-08-26       Impact factor: 2.847

8.  The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency.

Authors:  Xue Shao; Haruki Uojima; Taeang Arai; Yuji Ogawa; Toru Setsu; Masanori Atsukawa; Yoshihiro Furuichi; Yoshitaka Arase; Kazue Horio; Hisashi Hidaka; Takahide Nakazawa; Makoto Kako; Tatehiro Kagawa; Katsuhiko Iwakiri; Atsushi Nakajima; Shuji Terai; Yasuhito Tanaka; Wasaburo Koizumi
Journal:  Dig Dis       Date:  2021-11-22       Impact factor: 3.421

9.  MBOAT7-TMC4 rs641738 Is Not Associated With the Risk of Hepatocellular Carcinoma or Persistent Hepatitis B Infection.

Authors:  Peng Wang; Ying Li; Lu Li; Rong Zhong; Na Shen
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

10.  Association of TM6SF2 rs58542926 T/C gene polymorphism with hepatocellular carcinoma: a meta-analysis.

Authors:  Shan Tang; Jing Zhang; Ting-Ting Mei; Hai-Qing Guo; Xin-Huan Wei; Wen-Yan Zhang; Ya-Li Liu; Shan Liang; Zuo-Peng Fan; Li-Xia Ma; Wei Lin; Yi-Rong Liu; Li-Xia Qiu; Hai-Bin Yu
Journal:  BMC Cancer       Date:  2019-11-21       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.